DK2833914T3 - Adjuvanssystem til oral vaccineadministration - Google Patents
Adjuvanssystem til oral vaccineadministration Download PDFInfo
- Publication number
- DK2833914T3 DK2833914T3 DK13772028.0T DK13772028T DK2833914T3 DK 2833914 T3 DK2833914 T3 DK 2833914T3 DK 13772028 T DK13772028 T DK 13772028T DK 2833914 T3 DK2833914 T3 DK 2833914T3
- Authority
- DK
- Denmark
- Prior art keywords
- adjuvant
- antigen
- aluminum
- well
- ctl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Claims (8)
1. Immunologisk sammensætning til oral administration, der omfatter én eller flere C-type lectin- (CTL) receptorligander, ét eller flere aluminiumsadjuvanser og ét eller flere antigener og én eller flere acrylharpikspolymerer.
2. Immunologisk sammensætning ifølge krav 1, hvor acrylharpikspolymeren er en vandopløselig copolymer af ethylacrylat (EA), methylmethacrylat (MM) og trimethylammoniumethyl-methacrylatchlorid.
3. Immunologisk sammensætning ifølge krav 1, der endvidere omfatter et frostbeskyttelsesadditiv, eventuelt hvor frostbeskyttelsesadditivet er valgt fra gruppen bestående af trehalose, mannitol, lactose, sorbitol og saccharose og kombinationer deraf.
4. Fremgangsmåde til fremstilling af en oralt administrerbar immunogen sammensætning, der omfatter: adsorbering af et antigen og en C-type lectin- (CTL) receptorligand til et aluminiumsadjuvans; tilsætning af en acrylharpikspolymer med pH-afhængig opløselighed for at danne en vaccineformulering og tilsætning af vaccineformuleringen til opløsning med lavt pH for at præcipitere polymeren, hvorved der dannes en oralt administrerbar immunogen sammensætning.
5. Fremgangsmåde ifølge krav 4, hvor aluminiumsadjuvansen er aluminiumoxyhydroxid.
6. Fremgangsmåde ifølge krav 4, hvor CTL-receptorliganden er et saccharid.
7. Fremgangsmåde ifølge krav 4, hvor acrylharpiksen er en vanduopløselig copolymer af ethylacrylat (EA), methylmethacrylat (MM) og trimethylammoniumethyl-methacrylatchiorid.
8. Fremgangsmåde ifølge krav 4, der endvidere omfatter trinnet med atmosfærisk sprøjtefrysetørring af den oralt administrerbare immunogene sammensætning.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261686372P | 2012-04-04 | 2012-04-04 | |
PCT/US2013/000102 WO2013151595A1 (en) | 2012-04-04 | 2013-04-03 | Improved adjuvant system for oral vaccine adminstration |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2833914T3 true DK2833914T3 (da) | 2019-03-11 |
Family
ID=49300897
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK13772028.0T DK2833914T3 (da) | 2012-04-04 | 2013-04-03 | Adjuvanssystem til oral vaccineadministration |
Country Status (10)
Country | Link |
---|---|
US (3) | US20150079130A1 (da) |
EP (2) | EP3549605A1 (da) |
JP (1) | JP6240155B2 (da) |
KR (1) | KR101867428B1 (da) |
AU (1) | AU2013243971B2 (da) |
CA (1) | CA2903313C (da) |
DK (1) | DK2833914T3 (da) |
IL (1) | IL234937B (da) |
MX (1) | MX364946B (da) |
WO (1) | WO2013151595A1 (da) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL247301B (en) * | 2014-02-20 | 2022-07-01 | Vaxart Inc | Formulations for administration to the small intestine |
CA2988165C (en) * | 2014-06-20 | 2023-08-01 | University Of Saskatchewan | Exotoxin/thermolysin compositions and methods and uses for treating or preventing laminitis |
MX2018010858A (es) * | 2016-03-07 | 2019-05-22 | Glaxosmithkline Biologicals Sa | Particulas de liberacion de farmacos. |
KR102369740B1 (ko) | 2020-09-21 | 2022-03-02 | 부경대학교 산학협력단 | 자궁경부암 조기진단을 위한 모바일 질확대경 장치 |
CN113750228B (zh) * | 2021-09-25 | 2024-02-20 | 大连理工大学 | 一种冷冻保护剂在铝佐剂中的应用 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4133397A (en) * | 1996-10-28 | 1998-05-22 | Pfizer Inc. | Oral vaccines for young animals with an enteric coating |
ES2232934T3 (es) * | 1997-02-14 | 2005-06-01 | MERCK & CO., INC. | Formulaciones de vacunas a base de polinucleotidos. |
US7087235B2 (en) | 1997-06-25 | 2006-08-08 | The United States Of America As Represented By The Secretary Of The Army | Fusion protein of streptococcal pyrogenic exotoxins |
US20030162955A1 (en) * | 1998-03-17 | 2003-08-28 | Lionel Chalus | Isolated mammalian membrane protein genes; related reagents |
HUP0103396A3 (en) * | 1998-07-08 | 2002-05-28 | Kirin Amgen Inc Wilmington | Powdery preparation for mucosal administration containing polymeric medicine |
EP1046651A1 (en) * | 1999-04-19 | 2000-10-25 | Koninklijke Universiteit Nijmegen | Composition and method for modulating dendritic cell-T interaction |
WO2004018698A2 (en) * | 2002-08-20 | 2004-03-04 | Genitrix, Llc | Lectin compositions and methods for modulating an immune response to an antigen |
JP2006518748A (ja) * | 2003-02-20 | 2006-08-17 | ベクトン・ディキンソン・アンド・カンパニー | 改良されたワクチン接種のための大気圧噴霧凍結乾燥によって作製される組換えブドウ球菌エンテロトキシンb(<sb>r</sb>seb)の粉末処方物 |
GB0505518D0 (en) * | 2005-03-17 | 2005-04-27 | Chiron Srl | Combination vaccines with whole cell pertussis antigen |
EP2066348A1 (en) * | 2006-09-26 | 2009-06-10 | Alexion Pharmaceuticals, Inc. | Compositions and methods for enhancing an adjuvant |
JP5911799B2 (ja) * | 2009-08-12 | 2016-04-27 | シグモイド・ファーマ・リミテッドSigmoid Pharma Limited | ポリマーマトリックスおよび油相を含んで成る免疫調節組成物 |
GB0919690D0 (en) * | 2009-11-10 | 2009-12-23 | Guy S And St Thomas S Nhs Foun | compositions for immunising against staphylococcus aureus |
GB201101665D0 (en) * | 2011-01-31 | 2011-03-16 | Novartis Ag | Immunogenic compositions |
-
2013
- 2013-04-03 MX MX2014011806A patent/MX364946B/es active IP Right Grant
- 2013-04-03 EP EP19151134.4A patent/EP3549605A1/en not_active Withdrawn
- 2013-04-03 JP JP2015504545A patent/JP6240155B2/ja active Active
- 2013-04-03 US US13/261,964 patent/US20150079130A1/en not_active Abandoned
- 2013-04-03 KR KR1020147030919A patent/KR101867428B1/ko active IP Right Grant
- 2013-04-03 DK DK13772028.0T patent/DK2833914T3/da active
- 2013-04-03 EP EP13772028.0A patent/EP2833914B1/en active Active
- 2013-04-03 CA CA2903313A patent/CA2903313C/en active Active
- 2013-04-03 WO PCT/US2013/000102 patent/WO2013151595A1/en active Application Filing
- 2013-04-03 AU AU2013243971A patent/AU2013243971B2/en not_active Ceased
-
2014
- 2014-10-02 IL IL234937A patent/IL234937B/en unknown
-
2018
- 2018-12-06 US US16/212,088 patent/US20190105389A1/en not_active Abandoned
-
2020
- 2020-11-05 US US17/090,292 patent/US20210052725A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2013243971B2 (en) | 2017-01-05 |
US20210052725A1 (en) | 2021-02-25 |
CA2903313C (en) | 2019-10-22 |
AU2013243971A1 (en) | 2014-10-02 |
JP6240155B2 (ja) | 2017-11-29 |
EP2833914A1 (en) | 2015-02-11 |
WO2013151595A1 (en) | 2013-10-10 |
KR101867428B1 (ko) | 2018-07-19 |
MX2014011806A (es) | 2015-06-03 |
IL234937B (en) | 2021-10-31 |
KR20150002755A (ko) | 2015-01-07 |
EP2833914B1 (en) | 2019-01-16 |
EP2833914A4 (en) | 2016-03-30 |
MX364946B (es) | 2019-05-15 |
EP3549605A1 (en) | 2019-10-09 |
US20150079130A1 (en) | 2015-03-19 |
IL234937A0 (en) | 2014-12-31 |
US20190105389A1 (en) | 2019-04-11 |
CA2903313A1 (en) | 2013-10-10 |
JP2015512441A (ja) | 2015-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210052725A1 (en) | Adjuvant system for oral vaccine administration | |
US20230234850A1 (en) | Adjuvanted vaccines | |
US20070237826A1 (en) | Polymerized solid lipid nanoparticles for oral or mucosal delivery of therapeutic proteins and peptides | |
JP2011514337A (ja) | 糖ガラス化ウィルス様粒子(vlp) | |
US10736952B2 (en) | Multivalent VLP conjugates | |
JP2010105968A (ja) | カチオン性ナノゲルを用いる粘膜ワクチン | |
CN114340665A (zh) | 用于对佐剂疫苗乳剂进行喷雾干燥的组合物和方法 | |
US9216215B2 (en) | Adjuvant system for vaccine adjuvant | |
US20200405849A1 (en) | Vaccine system for vaccine adjuvant | |
Hendy | Improved Delivery of a Broadly Active Influenza Subunit Vaccine | |
Beukema | Intradermal administration of influenza accine ith trehalose and pullulan-based dissol ing microneedle arra s | |
Hassett | Ultra stable glassy state vaccines containing adjuvants | |
Lu | EVALUATION OF ALPHA-D-GLUCAN NANOPARTICLE AS A VACCINE ADJUVANT |